Johannes Hülsenbeck

Johannes Hülsenbeck

AbbVie Inc - Chicago / United States
Medical and Health Sciences / Hematology
AD Scientific Index ID: 4401033
-
person_outline Johannes Hülsenbeck's MOST POPULAR ARTICLES
1-) DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapyF Graf, J Fahrer, S Maus, A Morgenstern, F Bruchertseifer, ...PloS one 9 (2), e88239, 20141482014
2-) Clostridium difficile toxins: more than mere inhibitors of Rho proteinsH Genth, SC Dreger, J Huelsenbeck, I JustThe international journal of biochemistry & cell biology 40 (4), 592-597, 20081432008
3-) Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivoC Ostrau, J Hülsenbeck, M Herzog, A Schad, M Torzewski, KJ Lackner, ...Radiotherapy and Oncology 92 (3), 492-499, 20091352009
4-) Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicityJ Huelsenbeck, C Henninger, A Schad, KJ Lackner, B Kaina, G FritzCell death & disease 2 (8), e190-e190, 20111222011
5-) Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin BH Genth, J Huelsenbeck, B Hartmann, F Hofmann, I Just, R GerhardFEBS letters 580 (14), 3565-3569, 2006992006